Fulcrum Therapeutics plunges 55% on clinical hold for sickle cell treatments

Feb. 24, 2023 8:34 AM ETFulcrum Therapeutics, Inc. (FULC)By: Jonathan Block, SA News Editor

Close Up Image Of A Stock Market Graph

solarseven

  • Fulcrum Therapeutics (NASDAQ:FULC) has plummeted 55% in Friday premarket trading after the US FDA placed a full clinical hold on its Investigational New Drug application for sickle cell disease treatment FTX-6058.
  • The hold is due to previouslhy reported preclinical data. As a result of the hold, dosing in a phase 1b trial has been suspended.
  • Fulcrum CEO Robert Gould said that the FDA's questions relate "to modulation of the PRC2 complex and the preclinical data."
  • Seeking Alpha contributor Stephen Ayers recently rated Fulcrum (FULC) a hold.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.